Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter

다국어 초록 (Multilingual Abstract)

Background: This study compared the degree of sustained control of hyperthyroidism in patients with toxic multinodular goiter(TMNG) treated with long-term methimazole (LT-MMI) or radioactive iodine (RAI).
Methods: In this clinical trial, 130 untreated patients with TMNG were randomized to either LT-MMI or RAI treatment. Bothgroups were followed for 108 to 148 months, with median follow-up durations of 120 and 132 months in the LT-MMI and RAIgroups, respectively. Both groups of patients were followed every 1 to 3 months in the first year and every 6 months thereafter.
Results: After excluding patients in whom the treatment modality was changed and those who were lost to follow-up, 53 patients inthe LT-MMI group and 54 in the RAI group completed the study. At the end of the study period, 50 (96%) and 25 (46%) patientswere euthyroid, and two (4%) and 25 (46%) were hypothyroid in LT-MMI and RAI groups, respectively. In the RAI group, four(8%) patients had subclinical hyperthyroidism. The mean time to euthyroidism was 4.3±1.3 months in LT-MMI patients and 16.3±15.0 months in RAI recipients (P<0.001). Patients treated with LT-MMI spent 95.8%±5.9% of the 12-year study period in a euthyroid state, whereas this proportion was 72.4%±14.8% in the RAI-treated patients (P<0.001). No major treatment-related adverseevents were observed in either group.
Conclusion: In patients with TMNG, LT-MMI therapy is superior to RAI treatment, as shown by the earlier achievement of euthyroidism and the longer duration of sustained normal serum thyrotropin.

참고문헌 (Reference)

1 Azizi F, "Treatment of toxic multinodular goiter : comparison of radioiodine and long-term methimazole treatment" 29 : 625-630, 2019

2 Yano Y, "Treatment of autonomously functioning thyroid nodules at a single institution : radioiodine therapy, surgery, and ethanol injection therapy" 25 : 749-754, 2011

3 Franklyn JA, "The management of hyperthyroidism" 330 : 1731-1738, 1994

4 Canaris GJ, "The Colorado thyroid disease prevalence study" 160 : 526-534, 2000

5 Azizi F, "Systemic thyroid hormone status in treated Graves’ disease" 17 : e95385-, 2019

6 Amouzegar A, "Reference limit of thyrotropin(TSH)and free thyroxine(FT4)in thyroperoxidase positive and negative subjects : a population based study" 36 : 950-954, 2013

7 van Soestbergen MJ, "Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy : a comparison with Graves’ disease" 15 : 797-800, 1992

8 Reiners C, "Radioiodine therapy of thyroid autonomy" 29 (29): S471-S478, 2002

9 Nygaard B, "Radioiodine therapy for multinodular toxic goiter" 159 : 1364-1368, 1999

10 Saravanan P, "Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study" 57 : 577-585, 2002

11 Okosieme OE, "Primary therapy of Graves’ disease and cardiovascular morbidity and mortality : a linked-record cohort study" 7 : 278-287, 2019

12 Villagelin D, "Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment" 25 : 1282-1290, 2015

13 Malboosbaf R, "Long-term treatment with antithyroid drugs : efficacy and safety" 18 (18): e101487-, 2020

14 Ganji SS, "Long-term methimazole is as effective as radioiodine therapy for the treatment of toxic multinodular goiter" 31 : 185-188, 2019

15 Azizi F, "Long-term continuous methimazole or radioiodine treatment for hyperthyroidism" 15 : 477-484, 2012

16 Azizi F, "Long-term antithyroid drug treatment : a systematic review and meta-analysis" 27 : 1223-1231, 2017

17 Peterson SJ, "Is a normal TSH synonymous with"euthyroidism"in levothyroxine monotherapy" 101 : 4964-4973, 2016

18 Azizi F, "Increased remission rates after long-term methimazole therapy in patients with Graves’ disease : results of a randomized clinical trial" 29 : 1192-1200, 2019

19 Brandt F, "Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death : a Danish population-based register study" 23 : 408-413, 2013

20 Lillevang-Johansen M, "Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH" 102 : 2301-2309, 2017

21 Delshad H, "Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran : the vitality of periodic monitoring" 22 : 415-421, 2012

22 Samuels MH, "Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition" 26 : 347-355, 2016

23 Azizi F, "Effect of long-term continuous methimazole treatment of hyperthyroidism : comparison with radioiodine" 152 : 695-701, 2005

24 Lillevang-Johansen M, "Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk" 29 : 332-340, 2019

25 Boelaert K, "Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine" 98 : 1869-1882, 2013

26 El Kawkgi OM, "Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature" 95 : 3-12, 2021

27 Krohn K, "Clinical review 133 : progress in understanding the etiology of thyroid autonomy" 86 : 3336-3345, 2001

28 Ross DS, "2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis" 26 : 1343-1421, 2016

29 American Diabetes Association Professional Practice Committee, "2. Classification and diagnosis of diabetes : standards of medical care in diabetes-2022" 45 (45): S17-S38, 2022